Table 3 Clinical trials conducted using umbilical cord-derived mesenchymal stem cells for the treatment of SCI
From: Treatment of spinal cord injury with mesenchymal stem cells
References | Acute, subactute or chronic | AIS grade | Number of patients | Sources of MSCs | Route of administration | Number of cells | Frequency of injection | Safety outcome | Efficacy outcome |
|---|---|---|---|---|---|---|---|---|---|
[7] | Chronic | – | 22 | UC | Intrathecal | 1 × 106 UC-MSCs/kg b.w. | Weekly 4 times as a course (17, 4 and 1 patients received 1, 2 and 3 courses respectively) | No AE | 13/16 patients with incomplete SCI showed improvement in ASIA and IANR-SCIFRS score. 0/6 patients with complete SCI showed improvement |
[61] | Chronic | A | 34 | UC | Intraspinal | 4 × 107 UC-MSCs | 2 (separate by 10 days) | No AE | 7/10 (70%), 5/14 (36%) and 0/10 (0%) patients in the UC-MSC, rehabilitation and untreated control group showed improvement in ASIA score, Barthel Index and muscle tension |